Pharmacoeconomic comparison of Helicobacter pylori eradication regimens

Sancar M., Izzettin F. V. , Apikoglu-Rabus S., Besisik F. , Tozun N., Dulger G.

Pharmacy World and Science, vol.28, no.4, pp.207-214, 2006 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 4
  • Publication Date: 2006
  • Doi Number: 10.1007/s11096-006-9021-y
  • Journal Name: Pharmacy World and Science
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.207-214


Background Helicobacter pylori is the most important etiologic agent for development of peptic ulcer, chronic gastritis and gastric carcinomas. It is now well established that H. pylori eradication treatment is more cost-effective than acid suppressing therapies alone for the treatment of peptic ulcer disease. However, the comparative cost-effectiveness of various H. pylori eradication regimens is still not clear.